Skip to content
Discover J&J
Medicines & therapies
Medical devices & technology
Discover J&J
Medicines & therapies
Medical devices & technology
Careers
Media
Contact
locationPlaceholder
Choose your country or region
Global
Global
English
North America
North America (Regional)
English
Canada
English
Français
United States
English
Asia Pacific
Asia Pacific (Regional)
English
Australia
English
China
中文
Hong Kong
English
中文
Japan
日本
Korea
한국어
New Zealand
English
Europe, Middle East & Africa (EMEA)
EMEA (Regional)
English
Middle East - Africa
الشرق الأوسط و أفريقيا (عربي)
Austria
Deutsch
Belgium
English
Français
Netherlands
Bulgaria
БЪЛГАРСКИ
Croatia
Hrvatski
Czech Republic
čeština
Denmark
Dansk
Estonia
English
Finland
Suomi
France
Français
Germany
Deutsch
Greece
ΕΛΛΗΝΙΚΑ
Hungary
Magyar
Ireland
English
Israel
עברית
Italy
Italiano
Latvia
English
Lithuania
English
Netherlands
Netherlands
Norway
Norsk
Poland
Polski
Portugal
Português
Romania
Română
Russia
Pусский
Serbia
Srpski
Slovakia
Slovenčina
Slovenia
Slovenščina
South Africa
English
Spain
Español
Switzerland
Français
Deutsch
Sweden
Svensk
Turkey
Türkçe
United Kingdom
English
Latin America
Latin America (Regional)
Español
Argentina
Español
Bolivia
Español
Brazil
Português
Central America and the Caribbean
Español
Chile
Español
Colombia
Español
Ecuador
Español
Mexico
Español
Paraguay
Español
Peru
Español
Uruguay
Español
Healthcare areas
Oncology
Immunology
Neuroscience
Cardiopulmonary
Products
Clinical trials
Pipeline
Patient resources
Innovative Medicine
healthcare areas
Menu
Healthcare areas
Oncology
Immunology
Neuroscience
Cardiopulmonary
Products
Clinical trials
Pipeline
Patient resources
Careers
Media
Contact
Show Search
Search Query
Submit Search
Clear
Dictate search request
Search Results
No Results
Recently Viewed
Listening...
Sorry, I don't understand. Please try again
Innovative Medicine
/
Newsroom
Newsroom
The latest news from Johnson & Johnson Innovative Medicine.
Press releases
Search Query
Submit Search
Clear
Dictate search request
Listening...
Sorry, I don't understand. Please try again
Topic
All (1021)
Cardiopulmonary (96)
Communicable diseases (143)
Company news (20)
Immunology (181)
Neuroscience (62)
Oncology (321)
Sub areas
All (1021)
Autoantibody (83)
Gastroenterology (55)
Immunodermatology (38)
Maternal-fetal immunology (7)
Rare autoantibody (10)
Respiratory (3)
Rheumatic diseases (67)
Rheumatology (68)
There are 1,021 results that match your search.
Filters
Topic
All (1021)
Cardiopulmonary (96)
Communicable diseases (143)
Company news (20)
Immunology (181)
Neuroscience (62)
Oncology (321)
Sub areas
All (1021)
Autoantibody (83)
Gastroenterology (55)
Immunodermatology (38)
Maternal-fetal immunology (7)
Rare autoantibody (10)
Respiratory (3)
Rheumatic diseases (67)
Rheumatology (68)
Innovative Medicine
October 24, 2025
Icotrokinra long-term results affirm promise of targeted oral peptide with high rates of durable skin clearance and favorable safety profile in difficult-to-treat scalp and genital psoriasis
In areas of high impact, 72% of patients with scalp psoriasis and 85% with genital psoriasis treated with icotrokinra achieved site-specific clear or almost clear skin at Week 52 in Phase 3 ICONIC-TOTAL study 67% of patients treated with icotrokinra achieved overall rates of clear or almost clear skin by Week 24, which was maintained through Week 52 Icotrokinra continues to show potential with its standout combination of exceptional skin clearance and favorable safety profile in a once daily pill
Read more
Innovative Medicine
October 20, 2025
Johnson & Johnson’s INLEXZO™ (gemcitabine intravesical system) plus cetrelimab delivers strong pre-surgical results in patients with muscle invasive bladder cancer scheduled for radical cystectomy
Phase 2b SunRISe-4 study shows 38% of patients treated with INLEXZO™-based combination had no detectable cancer in the bladder prior to surgery Data support potential role of INLEXZO™ in treating muscle invasive bladder cancer
Read more
Innovative Medicine
October 19, 2025
Subcutaneous amivantamab delivers promising 45 percent overall response rate with median duration of 7.2 months in recurrent or metastatic head and neck cancer
Responses were rapid and durable, and tumor shrinkage was observed in 82 percent of patients New findings from this investigational study build on the strength of RYBREVANT® (amivantamab-vmjw) in non-small cell lung cancer and broadens its potential across additional solid tumors
Read more
Innovative Medicine
October 16, 2025
TECVAYLI® plus DARZALEX FASPRO® combination regimen significantly improves progression-free survival and overall survival versus standard of care
First Phase 3 study (MajesTEC-3) of an investigational combination to show benefit in PFS and OS in relapsed/refractory multiple myeloma as early as second line Independent Data Monitoring Committee (IDMC) recommended unblinding the study based on statistically significant results
Read more
Innovative Medicine
October 16, 2025
Johnson & Johnson receives U.S. FDA Priority Review for AKEEGA® (niraparib and abiraterone acetate dual-action tablet) in BRCA-mutated metastatic castration-sensitive prostate cancer
Read more
Innovative Medicine
October 15, 2025
Johnson & Johnson enters new era in solid tumors at ESMO 2025 with promising data across multiple cancer types
First report of subcutaneous amivantamab demonstrates compelling clinical activity in recurrent or metastatic head and neck cancer, building on strength in colorectal cancer and EGFR-mutated lung cancer New analysis and recent U.S. FDA Fast Track designation underscore promise of first-in-class pasritamig for prostate cancer
Read more
Load More